1. Academic Validation
  2. Dihydropyrimidinase deficiency: structural organization, chromosomal localization, and mutation analysis of the human dihydropyrimidinase gene

Dihydropyrimidinase deficiency: structural organization, chromosomal localization, and mutation analysis of the human dihydropyrimidinase gene

  • Am J Hum Genet. 1998 Sep;63(3):717-26. doi: 10.1086/302022.
N Hamajima 1 M Kouwaki P Vreken K Matsuda S Sumi M Imaeda S Ohba K Kidouchi M Nonaka M Sasaki N Tamaki Y Endo R De Abreu J Rotteveel A van Kuilenburg A van Gennip H Togari Y Wada
Affiliations

Affiliation

  • 1 Department of Pediatrics, Nagoya City University Medical School, Nagoya City Higashi General Hospital, Nagoya, Japan. [email protected]
PMID: 9718352 DOI: 10.1086/302022
Abstract

Dihydropyrimidinase (DHP) deficiency (MIM 222748) is characterized by dihydropyrimidinuria and is associated with a variable clinical phenotype. This disease might be associated with a risk of 5-fluorouracil toxicity, although no cases have been reported. We present here both the molecular characterization of the human DHP gene and, for the first time, the mutations causing DHP deficiency. The human DHP gene spans >80 kb and consists of 10 exons. It has been assigned to 8q22, by FISH. We performed mutation analysis of genomic DNA in one symptomatic and five asymptomatic individuals presenting with dihydropyrimidinuria. We identified one frameshift mutation and five missense mutations. Two related Japanese adult subjects were homozygous for the Q334R substitution, whereas two other, unrelated Japanese infant subjects were heterozygous for the same mutation, but this mutation is not common in the Japanese population. A Caucasian pediatric patient exhibiting epileptic attacks, dysmorphic features, and severe developmental delay was homozygous for W360R. Using a eukaryotic expression system, we showed that all mutations reduced Enzyme activity significantly, indicating that these are crucial DHP deficiency-causing mutations. There was no significant difference, in residual activity, between mutations observed in the symptomatic and those observed in the asymptomatic individuals.

Figures